Butyrophilin subfamily 3 member A1 (BTN3A1)

Butyrophilin subfamily 3 member A1 (BTN3A1, also known as CD277) is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily, closely related to the B7 protein family[2][7]. Expressed on diverse cell types including epithelial cells, macrophages, and many tumors, BTN3A1 is best known for its pivotal role in modulating immune responses, particularly by sensing intracellular phosphoantigen metabolites (such as isoprenoid intermediates) that accumulate during cellular stress, infection, or tumorigenesis[2][5][7]. The intracellular B30.2 domain of BTN3A1 binds these phosphoantigens, which triggers conformational changes leading to interaction with BTN2A1 at the cell surface and subsequent activation of Vγ9Vδ2 T cells—a critical γδ T cell subset involved in tumor surveillance and rapid response to infected or transformed cells[1][4][7]. The BTN3A1/BTN2A1 system serves as both an immunological sensor and co-stimulatory complex, making it a novel therapeutic target for immunomodulatory drugs and cancer immunotherapy approaches, although direct small molecule or antibody therapeutics are still preclinical[2][4]. No widely validated clinical biomarkers or approved drugs target BTN3A1 directly, but pharmacological strategies like aminobisphosphonates leverage its pathway for clinical benefit in related contexts[2].

Other names

CD277butyrophilin 3A1BTF5BT3.1B30.2 domain-containing protein

Induction of γδ T cell activation through intracellular phosphoantigen binding, leading to receptor (BTN3A1/BTN2A1) conformational changes and extracellular signaling Antibody-mediated modulation of BTN3A1/BTN2A1 complex to either mimic or block activation